Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Citicoline

Citicoline (CDP-Choline / Cognizin) · also known as CDP-choline, Cognizin, Citicoline

Oral citicoline can supply choline, and human studies show higher plasma choline and uridine. Animal studies suggest it can affect brain phospholipid synthesis and dopamine-related markers, but these effects have not been confirmed in humans.

Typical dose: 250–1000 mg/day, taken in the morning or before focused mental work
Absorption and forms: Oral intestinal bioavailability is reported to exceed 90%. After oral intake, the main increases in circulation are choline and uridine. The claim that cytidine itself is the main form that enters the brain is inaccurate. Choline can cross the blood-brain barrier and takes part in synthesizing acetylcholine and phospholipids in the brain.

Clinical uses and human evidence

Memory

BeneficialGrade B · Moderate evidence
Studies (1)
  1. Nakazaki 2021 · J Nutr · RCT · n=100 — Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Attention and focus

BeneficialGrade B · Moderate evidence
Studies (1)
  1. McGlade 2019 · J Atten Disord · RCT · n=75 — The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males

Age-related cognitive decline

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Bonvicini 2023 · Nutrients · Meta-analysis — Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis

Macular and vision protection

Mixed resultsGrade C · Preliminary evidence
Studies (2)
  1. Lanza 2019 · Front Pharmacol · RCT · n=60 — Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
  2. Anton 2022 · Life (Basel) · RCT · n=73 — The Effect of Oral Citicoline and Docosahexaenoic Acid on the Visual Field of Patients with Glaucoma: A Randomized Trial

Mechanisms of action

Cholinergic neurotransmission (ACh precursor supply and AChE inhibition)

★★★☆☆Mechanism evidence: grade B

Citicoline provides choline, which can serve as a raw material for acetylcholine and phospholipid synthesis. However, how much is actually used depends on physiological state, and choline supply is not necessarily the rate-limiting step. Human studies measured higher plasma choline, and signals from choline-containing compounds in the brain also changed. This is not enough to confirm that acetylcholine synthesis or release in the brain clearly increases at usual doses.

References (2)
  1. Wurtman 2000 · Randomized crossover study in 12 people: plasma choline and uridine rose after an oral 500 mg dose
  2. Babb 1996 · Small human study: changes in a brain signal from choline-containing compounds were observed, and this signal was not acetylcholine

Monoamine neurotransmitter balance (dopamine, norepinephrine, 5-HT)

★★★☆☆Mechanism evidence: grade CSecondary target

In animal studies, rats given 300 mg/kg by intraperitoneal injection had higher striatal dopamine content, and striatal tyrosine hydroxylase activity also changed. This suggests dopamine metabolism may shift. These results come from animals, and the dose and route differ from usual oral dosing. There is still no reliable target validation in humans.

References (2)
  1. Shibuya 1981 · Rat study: striatal dopamine content rose after intraperitoneal injection of 300 mg/kg
  2. Martinet 1981 · Rat study: changes in striatal tyrosine hydroxylase activity were observed

Neurotrophic factor synthesis and TrkB/A receptor activation

★★☆☆☆Mechanism evidence: grade CSecondary target

In rats with nerve injury, a higher dose of citicoline given by intraperitoneal injection raised BDNF gene expression in the trigeminal ganglion on day 3. This is an animal result at a high dose, so it cannot be assumed that usual oral dosing has the same effect in the human brain. Changes in synaptophysin also do not represent the BDNF or NGF pathway.

References (1)
  1. Susilowati 2024 · Rat study: after nerve injury, high-dose intraperitoneal citicoline raised BDNF gene expression in the trigeminal ganglion on day 3

Safety and drug interactions

People who are prone to nervous overstimulation or insomnia should avoid taking it in the evening or at bedtime. Very mild gastrointestinal upset occasionally occurs.
Open in the interactive app ›